This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krug, L. M. Articles by Sirotnak, F. M. Search for Related Content PubMed PubMed Citation Articles by Krug, L. M. Articles by Sirotnak, F. M.

10-Propargyl-10-deazaaminopterin

An Antifolate with Activity in Patients with Previously Treated Non-Small Cell Lung Cancer¹

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine [L. M. K., C. G. A., M. G. K., V. A. M., L. T., B. P., V. B., K. K. N.], Program of Molecular Pharmacology and Experimental Therapeutics [N. Z. K., W. T., F. M. S.], Departments of Radiology [M. S. G.] and Epidemiology and Biostatistics [E. V.], Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University New York, New York 10021

Purpose: 10-propargyl-10-deazaaminopterin (PDX) has superior antitumor efficacy in mouse xenograft models, likely attributable to increased uptake by the RFC-1 folate transporter and greater intracellular polyglutamylation. In a previous Phase I trial, stomatitis was the dose-limiting (and only clinically significant) toxicity of PDX. The recommended Phase II dose was 150 mg/m² i.v. every 2 weeks. Responses observed in patients with non-small cell lung cancer (NSCLC) in the Phase I trial prompted this Phase II trial.

Experimental Design: Patients had stage IIIB or IV NSCLC and either no previous chemotherapy or progression after initial response or stable disease to one previous chemotherapy regimen. Initially, PDX was administered at a dose of 150 mg/m² every 2 weeks. However, to decrease the frequency of stomatitis, the last 10 patients were treated at a dose of 135 mg/m². We planned to correlate PDX effects with folate and homocysteine levels and the expression of genes associated with folate transport and polyglutamylation.

Results: Thirty-nine patients were enrolled, 38 of whom were evaluable for response. Four patients had confirmed, major objective responses (10% based on intent to treat, 95% confidence interval 3–25) lasting 4, 9, 12, and 15 months. Twelve patients (31%) had stable disease. The median survival was 13.5 months. The predicted 1- and 2-year survival rates were 56 and 36%, respectively. Two patients (5%) suffered grade 4 stomatitis, and 6 (15%) had grade 3. No clinically significant myelosuppression occurred. No correlation between homocysteine or serum folate levels and severity of stomatitis was observed. Area under the curve (calculated using a limited sampling model) correlated with mucositis grade. A trend was noted between folate transporter expression and treatment effect.

Conclusions: The broad applicability of this new antifolate with limited toxicity and proven efficacy in NSCLC encourage further development of this compound. Several trials are now underway combining PDX with other chemotherapeutic agents and testing its efficacy in other cancers.

This article has been cited by other articles:

				C. G. Azzoli, L. M. Krug, J. Gomez, V. A. Miller, M. G. Kris, M. S. Ginsberg, R. Henry, J. Jones, L. Tyson, M. Dunne, et al. A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors Clin. Cancer Res., May 1, 2007; 13(9): 2692 - 2698. [Abstract] [Full Text] [PDF]